Chronic Obstructive Pulmonary Disease
Conditions
Keywords
to verify accurrancy of data collected by the NOWOX
Brief summary
The purpose of this study is to evaluate the duration of oxygen use recorded by the NOWOX, under usual conditions of daily living, in patients with chronic obstructive respiratory disease requiring oxygen therapy.
Detailed description
Long Term Oxygen Therapy (LTOT) is one of the main non pharmacologic treatments for patients with severe lung disease. This continuous or sub-continuous oxygen supplementation is generally introduced at home in patients who have chronic cardio respiratory failure and severe resting hypoxemia to maintain sufficient blood oxygenation and therefore preserve vital organ function. LTOT effectiveness has mainly been evaluated and documented in patients with COPD, which also accounts for most of its prescriptions. In these patients, LTOT has been shown to have a beneficial impact on haemodynamics, exercise capacity, lung mechanics and mental state. Its implementation was furthermore associated with reduced yearly hospitalisation days and increased survival Measuring adherence is an extremely important and under-evaluated component of oxygen therapy. NOWOX, medical device has been designed,developed and manufactured to measure adherence to LTOT and additionally to measure patient's respiration rate
Interventions
DEVICENOWOX
one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
Sponsors
Air Liquide SA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patient aged ≥ 18 years and ≤ 75 years, * Having a documented diagnosis of moderately severe to severe chronic obstructive respiratory disease * Hospitalised or out-patient requiring transient or long term oxygen therapy, * Able to be weaned from oxygen for several consecutive minutes (around 30 minutes, SpO2 at rest on room air should not drop \< 85%), * Able to read * Willing and able to complete the requirements of this study including providing his/her signature for the written informed consent.
Exclusion criteria
* Clinically unstable patient, * Any contraindication to perform a light cycling exercise, according to the 2003 ATS/ACCP guidelines * Tracheostomy, * Nasal obstruction or acute rhinitis occurring in the week prior to selection, * For female patient: * Pregnant, * Positive urinary pregnancy test * Lactating mother or lack of efficient contraception * Clinically significant or uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, autoimmune, neurological or psychiatric disorders which may interfere with the study procedures, * Known allergic reactions to medical material compounds used in the study * Drug abuse or psychic disorders * Legal status which prohibits informed consent, * Participation in any interventional clinical trial within 30 days prior to selection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary performance criterion is the overall estimated duration of oxygen use | 6 hours |
Secondary
| Measure | Time frame |
|---|---|
| secondary performance criterion: instantaneous respiration rate recorded by the NOWOX | 6 hours |
| secondary performance criterion: patient's satisfaction questionnaire on the NOWOX | 1 hour |
Countries
France
Outcome results
None listed